A study on side effects such as nausea and vomitus after medication to prevent excessive bleeding after a caesarean section
| ISRCTN | ISRCTN95504420 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN95504420 |
| Secondary identifying numbers | OBGYN-1 |
- Submission date
- 03/02/2013
- Registration date
- 28/02/2013
- Last edited
- 07/03/2018
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Pregnancy and Childbirth
Plain English summary of protocol
Background and study aims
At the end of a cesarean section in Belgium, in general some medication is given to the mother to prevent excessive bleeding. The two products used most frequently are called carbetocin and oxytocin and work well. No difference has been demonstrated as far as the effect on prevention of bleeding is concerned. A major side effect of this kind of medication is nausea and vomitus and a lowering of blood pressure resulting in dizziness. The aim of the present study is to compare nausea, vomiting and changes in blood pressure between carbetocin and oxytocin.
Who can participate?
Any pregnant woman for whom a caesarean section is planned in a term ( full grown) pregnancy without any other complication can participate.
What does the study involve?
Participants are randomly allocated to one of two groups. All women receive an intravenous medication to prevent bleeding and no one (participant, operating or treating team) will not know whether the medication used is carbetocin or oxytocin.
What are the possible benefits and risks of participating?
There is no difference with routine management during which both medications are used. The results of this study will help future patients to receive the product with the fewest side effects.
Where is the study run from?
The study will be run in the Obstetrics Ward at Antwerp University Hospital UZA, Belgium.
When is the study starting and how long is it expected to run for?
The study will be running for one year and will start in March 2013.
Who is funding the study?
This study is not funded by any pharmaceutical company, all costs are taken care of by the local Fund for perinatal Medicine of the Department of Obstetrics at Antwerp University Hospital
Who is the main contact?
Prof Dr Yves Jacquemyn
Yves.jacquemyn@uza.be
Contact information
Scientific
Wilrijkstraat 10
Edegem
2650
Belgium
| yves.jacquemyn@uza.be |
Study information
| Study design | Prospective randomized controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
| Scientific title | OBGYN-1: A randomized controlled trial on nausea, vomitus and blood pressure changes comparing carbetocine versus oxytocine in the prevention of hemorrhage after caesarean section |
| Study acronym | NAVOCASY |
| Study objectives | Single shot intraveneous carbetocin is accompanied with more nausea and vomitus as compared to intravenous oxytocin. |
| Ethics approval(s) | Ethics Committee Ethisch Comité Universitair Zieknhusi Antwerpen, 21/02/2011, ref: B300201110299 |
| Health condition(s) or problem(s) studied | Pregnancy and delivery |
| Intervention | Standard intravenous carbetocin vs standard intravenous oxytocin |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Carbetocin, oxytocin |
| Primary outcome measure | From the moment the participant enters the operating theatre until one hour later, blood pressure and heart frequence are carefully registered every 5 minutes or more as during routine monitoring of surgery. Nausea and vomitus are evaluated before surgery (just before incision), during surgery: before giving the intravenous medication and after 5, 10 and 15 minutes based on the standardized scale: 0: no nausea, no vomitus 1: mild nausea, no vomiting 2: nausea but with retching, no vomiting 3: nausea and vomiting |
| Secondary outcome measures | Any other complaint |
| Overall study start date | 15/02/2013 |
| Completion date | 15/02/2014 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Female |
| Target number of participants | 60 |
| Key inclusion criteria | Term uncomplicated pregnant women who undergo a planned cesarean section |
| Key exclusion criteria | 1. Unplanned caesarean section 2. Complications including: hypertension, preterm labour, any gastrointestinal or cardiovascular disease necessitating treatment |
| Date of first enrolment | 15/02/2013 |
| Date of final enrolment | 15/02/2014 |
Locations
Countries of recruitment
- Belgium
Study participating centre
2650
Belgium
Sponsor information
Hospital/treatment centre
Department of Obstetrics
Wilrijkstraat 10
Edegem
2650
Belgium
| yves.jacquemyn@uza.be | |
"ROR" |
https://ror.org/01hwamj44 |
Funders
Funder type
Hospital/treatment centre
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 02/01/2018 | Yes | No |
Editorial Notes
07/03/2018: Publication reference added.
